These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 34204943)

  • 1. Pharmacokinetics and Pharmacodynamics of Meropenem by Extended or Continuous Infusion in Low Body Weight Critically Ill Patients.
    Luque S; Benítez-Cano A; Larrañaga L; Sorlí L; Navarrete ME; Campillo N; Carazo J; Ramos I; Adalia R; Grau S
    Antibiotics (Basel); 2021 Jun; 10(6):. PubMed ID: 34204943
    [No Abstract]   [Full Text] [Related]  

  • 2. Impact of cumulative fluid balance on the pharmacokinetics of extended infusion meropenem in critically ill patients with sepsis.
    Pařízková RČ; Martínková J; Havel E; Šafránek P; Kaška M; Astapenko D; Bezouška J; Chládek J; Černý V
    Crit Care; 2021 Jul; 25(1):251. PubMed ID: 34274013
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative Plasma and Interstitial Tissue Fluid Pharmacokinetics of Meropenem Demonstrate the Need for Increasing Dose and Infusion Duration in Obese and Non-obese Patients.
    Busse D; Simon P; Schmitt L; Petroff D; Dorn C; Dietrich A; Zeitlinger M; Huisinga W; Michelet R; Wrigge H; Kloft C
    Clin Pharmacokinet; 2022 May; 61(5):655-672. PubMed ID: 34894344
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Beta-lactam exposure and safety in intermittent or continuous infusion in critically ill children: an observational monocenter study.
    Debray A; Callot D; Hirt D; Bille E; Renolleau S; Chouchana L; Tréluyer JM; Oualha M; Béranger A
    Eur J Pediatr; 2023 Mar; 182(3):965-973. PubMed ID: 36422708
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of a dosing algorithm for meropenem in critically ill patients based on a population pharmacokinetic/pharmacodynamic analysis.
    Ehmann L; Zoller M; Minichmayr IK; Scharf C; Huisinga W; Zander J; Kloft C
    Int J Antimicrob Agents; 2019 Sep; 54(3):309-317. PubMed ID: 31229669
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reappraisal of the Optimal Dose of Meropenem in Critically Ill Infants and Children: a Developmental Pharmacokinetic-Pharmacodynamic Analysis.
    Wang ZM; Chen XY; Bi J; Wang MY; Xu BP; Tang BH; Li C; Zhao W; Shen AD
    Antimicrob Agents Chemother; 2020 Jul; 64(8):. PubMed ID: 32513801
    [TBL] [Abstract][Full Text] [Related]  

  • 7. OTAC: Optimization of Antibiotic Therapy in Critically ill Patients. Using beta-lactam antibiotics by continuous infusion.
    Esteve-Pitarch E; Padullés-Zamora A; Maisterra-Santos K; Colom-Codina H; Cobo-Sacristán S
    Farm Hosp; 2019 Sep; 43(5):151-157. PubMed ID: 31469627
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population Pharmacokinetics and Pharmacodynamic Target Attainment of Meropenem in Critically Ill Young Children.
    Cies JJ; Moore WS; Enache A; Chopra A
    J Pediatr Pharmacol Ther; 2017; 22(4):276-285. PubMed ID: 28943823
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-Time TDM-Based Expert Clinical Pharmacological Advice Program for Attaining Aggressive Pharmacokinetic/Pharmacodynamic Target of Continuous Infusion Meropenem in the Treatment of Critically Ill Patients with Documented Gram-Negative Infections Undergoing Continuous Veno-Venous Hemodiafiltration.
    Gatti M; Rinaldi M; Tonetti T; Siniscalchi A; Viale P; Pea F
    Antibiotics (Basel); 2023 Oct; 12(10):. PubMed ID: 37887225
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimized meropenem dosage regimens using a pharmacokinetic/pharmacodynamic population approach in patients undergoing continuous venovenous haemodiafiltration with high-adsorbent membrane.
    Padullés Zamora A; Juvany Roig R; Leiva Badosa E; Sabater Riera J; Pérez Fernández XL; Cárdenas Campos P; Rigo Bonin R; Alía Ramos P; Tubau Quintano F; Sospedra Martinez E; Colom Codina H
    J Antimicrob Chemother; 2019 Oct; 74(10):2979-2983. PubMed ID: 31335959
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Population pharmacokinetics of meropenem in critically ill children with different renal functions.
    Rapp M; Urien S; Foissac F; Béranger A; Bouazza N; Benaboud S; Bille E; Zheng Y; Gana I; Moulin F; Lesage F; Renolleau S; Tréluyer JM; Hirt D; Oualha M
    Eur J Clin Pharmacol; 2020 Jan; 76(1):61-71. PubMed ID: 31654149
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Meropenem for the Pharmacological Treatment of Severe Infections in Critically Ill Pediatric Patients: Breakthrough Standard Treatment Strategies Based on PK/PD.
    He X; Liu X; Gong X; Wang L; Chen F
    Curr Drug Metab; 2023; 24(1):5-15. PubMed ID: 36974414
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics and Pharmacodynamics of Extended-Infusion Cefepime in Critically Ill Patients Receiving Continuous Renal Replacement Therapy: A Prospective, Open-Label Study.
    Philpott CD; Droege CA; Droege ME; Healy DP; Courter JD; Ernst NE; Harger NJ; Foertsch MJ; Winter JB; Carter KE; Van Fleet SL; Athota K; Mueller EW
    Pharmacotherapy; 2019 Nov; 39(11):1066-1076. PubMed ID: 31549737
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intrapulmonary concentrations of meropenem administered by continuous infusion in critically ill patients with nosocomial pneumonia: a randomized pharmacokinetic trial.
    Benítez-Cano A; Luque S; Sorlí L; Carazo J; Ramos I; Campillo N; Curull V; Sánchez-Font A; Vilaplana C; Horcajada JP; Adalia R; Bermejo S; Samsó E; Hope W; Grau S
    Crit Care; 2020 Feb; 24(1):55. PubMed ID: 32066497
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of renal function in risk assessment of target non-attainment after standard dosing of meropenem in critically ill patients: a prospective observational study.
    Ehmann L; Zoller M; Minichmayr IK; Scharf C; Maier B; Schmitt MV; Hartung N; Huisinga W; Vogeser M; Frey L; Zander J; Kloft C
    Crit Care; 2017 Oct; 21(1):263. PubMed ID: 29058601
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factors associated with meropenem pharmacokinetic/pharmacodynamic target attainment in septic critically ill patients treated with extended intermittent infusion or continuous infusion.
    Tournayre S; Mathieu O; Villiet M; Besnard N; Brunot V; Daubin D; Platon L; Corne P; Klouche K; Larcher R
    Int J Antimicrob Agents; 2023 Aug; 62(2):106868. PubMed ID: 37244425
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Does Prolonged Infusion Time Really Improve the Efficacy of Meropenem Therapy? A Prospective Study in Critically Ill Patients.
    Zhao YC; Zou Y; Xiao YW; Wang F; Zhang BK; Xiang DX; Yu F; Luo H; Sandaradura I; Yan M
    Infect Dis Ther; 2022 Feb; 11(1):201-216. PubMed ID: 34748194
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics and pharmacodynamics of continuous infusion meropenem in overweight, obese, and morbidly obese patients with stable and unstable kidney function: a step toward dose optimization for the treatment of severe gram-negative bacterial infections.
    Pai MP; Cojutti P; Pea F
    Clin Pharmacokinet; 2015 Sep; 54(9):933-41. PubMed ID: 25850987
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Does Two-Step Infusion Improve the Pharmacokinetics/Pharmacodynamics Target Attainment of Meropenem in Critically Ill Patients?
    Chen J; Wang Q; Li S; Han R; Wang C; Cheng S; Yang B; Diao L; Yang T; Sun D; Zhang D; Dong Y; Wang T
    J Pharm Sci; 2024 Sep; 113(9):2904-2914. PubMed ID: 38996917
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of meropenem in critically ill patients in Saudi Arabia.
    Alsultan A; Dasuqi SA; Aljamaan F; Omran RA; Syed SA; AlJaloud T; AlAhmadi A; Alqahtani S; Hamad MA
    Saudi Pharm J; 2021 Nov; 29(11):1272-1277. PubMed ID: 34819789
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.